Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genedata Announces Expansion into Biopharma Process Development

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
Established, integrated biologics platform extends scope to support bioprocess development workflows.

Genedata announce that it is extending its enterprise biologics R&D solution to support bioprocess development workflows.  A first-in-class software solution for integrated biopharma data management, Genedata Biologics enables biologics companies to more efficiently discover, develop, and manufacture novel, as well as generic, biotherapeutics. Genedata Biologics provides tailored functionalities to enhance process efficiency, which complement established antibody discovery and protein engineering functionalities. 

Towards an Integrated Platform for Cell and Process Development:  Significant Efficiency and Quality Gains

Genedata Biologics, an enterprise workflow system, now also supports process and cell line development units. The platform provides tools for the optimization of protein expression, purification, and analytics processes. These tools are essential for efficient and successful production of high-quality biologics for R&D and large-scale product manufacturing. Optimizing expression and purification processes requires various groups to work in a division-of-labor environment (e.g. molecular biology, cell line engineering, assays and analytics, and bioprocess development groups). Genedata Biologics captures all relevant data, from the definition of the desired biomolecule’s blueprint to the final product, including all production process-relevant parameters (e.g. transfection protocols, cell culture and fermentation conditions, media, purification methods, and product titers and quality parameters). All data are traced back to the plasmids and cell lines and can be analyzed together. The system also integrates with upstream and downstream processes, and now comes with sample and inventory management that streamlines tracking of samples and aliquots.

The system provides easy-to-use, comprehensive, and automated data capture, processing and reporting capabilities. It minimizes duplication of work, eliminates error-prone manual activities, and provides extremely valuable transparency for efficient decision making, so that high-quality proteins can be delivered faster.

“Having successfully supported important workflows in biopharma discovery, we now set our sights on extending Genedata Biologics to biopharma development with an initial focus on cell line and bioprocess development,” said Dr. Othmar Pfannes, CEO of Genedata. “Our innovative platform aids in the rapid and systematic development of optimized bioprocesses, and specifically helps to standardize and streamline cell line development. This brings us another step closer in providing our customers with a fully integrated platform that supports the complete biopharmaceutical R&D process.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Kymab Implements Genedata Biologics for High-throughput Antibody Discovery
Genedata Biologics™ integrated workflow platform used to increase throughput and automation of Kymab’s transgenic mice-based discovery platforms.
Tuesday, November 17, 2015
Merck Serono Chooses Genedata Biologics to Streamline Antibody Discovery Processes
Global deployment of Genedata Biologics across multiple protein therapeutics R&D groups to standardize workflows and improve efficiency.
Thursday, July 23, 2015
Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata, Bayer Pharma AG Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!